Evidence map›Paper›PMID 38705947›Full record

ArticleActa parasitologica2024

Piperine Enhances Antimalarial Activity of Methyl Gallate and Palmatine Combination.

Adegbenro P Adegunloye, Joseph O Adebayo

Abstract read
PubMed Publisher
In one paragraph

Article in Acta parasitologica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Adegbenro P AdegunloyeDepartment of Biochemistry, Faculty of Life Sciences, University of Ilorin, Ilorin, Nigeria.ORCID http://orcid.org/0000-0002-5506-2386
Joseph O AdebayoDepartment of Biochemistry, Faculty of Life Sciences, University of Ilorin, Ilorin, Nigeria. jadebayo@unilorin.edu.ng.ORCID http://orcid.org/0000-0003-3151-2247

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeArtemisinin combination therapies, the first-line antimalarials in Nigeria, have reportedly suffered multiple failures in malaria treatment, hence the search for novel combination of other compounds. Methyl gallate and palmatine have been reported to exhibit antiplasmodial activities but the antimalarial activity of their combination has not been evaluated. Therefore, the evaluation of the combination of methyl gallate and palmatine for antimalarial activity in vitro and in vivo in the presence of piperine was carried out. MATERIALS AND

methodsThe inhibitory potential of methyl gallate and palmatine combination on β-hematin (hemozoin) formation was studied in vitro. Also, the antimalarial activity of methyl gallate and palmatine combination with/without a bioenhancer (piperine) was evaluated in Plasmodium berghei NK65-infected mice.

resultsMethyl gallate and palmatine in the ratio 3:2 acted synergistically in vitro and had the highest inhibitory effect (IC

conclusionThe 3:2 combination of methyl gallate and palmatine in the presence of piperine exhibited antimalarial activity in vivo, possibly by synergistic inhibition of hemozoin formation which may cause accumulation of haem within the food vacuole of Plasmodium spp. and its death.

Indexed as

AlkaloidsAntimalarialsBenzodioxolesBerberine AlkaloidsDrug SynergismGallic AcidMalariaPiperidinesPlasmodium bergheiPolyunsaturated AlkamidesAnimalsHemeproteinsInhibitory Concentration 50MiceParasitemiaAlkaloidsAntimalarialsBenzodioxolesBerberine AlkaloidsGallic AcidHemeproteinshemozoinmethyl gallatepalmatinePiperidinespiperinePolyunsaturated AlkamidesAntimalarialBioenhancerDrug combinationMethyl gallatePalmatinePiperine

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.